A carregar...

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Holmström, Morten Orebo, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5674967/
https://ncbi.nlm.nih.gov/pubmed/29147619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1358334
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!